Luis Querol1, Gisela Nogales-Gadea, Ricardo Rojas-Garcia, Jordi Diaz-Manera, Julio Pardo, Angel Ortega-Moreno, Maria Jose Sedano, Eduard Gallardo, Jose Berciano, Rafael Blesa, Josep Dalmau, Isabel Illa. 1. From the Neuromuscular Diseases Unit (L.Q., G.N.-G., R.R.-G., J.D.-M., E.G., R.B., I.I.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona; Centro para la Investigación Biomédica en Red en Enfermedades Neurodegenerativas (L.Q., G.N.-G., R.R.-G., J.D.-M., M.J.S., E.G., J.B., I.I.), CIBERNED, Madrid; Department of Neurology (J.P.), Hospital Clínico de Santiago, Santiago de Compostela; Department of Neurology (A.O.-M.), Hospital Virgen de las Nieves, Granada; Department of Neurology (M.J.S., J.B.), University Hospital Marqués de Valdecilla (IFIMAV) and University of Cantabria; Department of Neurology (J.D.), Hospital Clinic, Universitat de Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona; and Institució Catalana de Recerca i Estudis Avançats (J.D.), Barcelona, Spain.
Abstract
OBJECTIVE: To describe the frequency of antibodies against neurofascin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and the associated clinical features. METHODS: Immunocytochemistry was used to identify antibodies to neurofascin 155 (NF155) and 186. Serum reactivity with paranodes and brain tissue was tested with immunohistochemistry of teased-nerve fibers and rat brain. Antibody titers and immunoglobulin (Ig) G isotypes were determined using ELISA. Clinical information was obtained retrospectively. RESULTS: Two of 53 patients, but none of 204 controls, had antibodies to NF155 (p = 0.041). The 2 patients with NF155 antibodies developed severe polyradiculoneuropathy with predominant distal weakness that was refractory to IVIg. Eight additional patients with IVIg-refractory CIDP were then identified from a national database; 2 of them with the same clinical features also had NF155 antibodies. Overall, 3 of the 4 patients with NF155 antibodies had a disabling and characteristic tremor (high amplitude, low frequency, postural, and intention). Patients' antibodies reacted with the paranodes in teased-nerve fibers and with the neuropil of rat cerebellum, brain, and brainstem. Anti-NF155 antibodies were predominantly of the IgG4 isotype in all patients. CONCLUSION: Patients with CIDP positive for IgG4 NF155 antibodies constitute a specific subgroup with a severe phenotype, poor response to IVIg, and disabling tremor. Autoantibodies against paranodal structures associate with distinct clinical features in CIDP and their identification has diagnostic, prognostic, and therapeutic implications. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that autoantibodies to NF155 identify a CIDP subtype characterized by severe neuropathy, poor response to IVIg, and disabling tremor.
OBJECTIVE: To describe the frequency of antibodies against neurofascin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and the associated clinical features. METHODS: Immunocytochemistry was used to identify antibodies to neurofascin 155 (NF155) and 186. Serum reactivity with paranodes and brain tissue was tested with immunohistochemistry of teased-nerve fibers and rat brain. Antibody titers and immunoglobulin (Ig) G isotypes were determined using ELISA. Clinical information was obtained retrospectively. RESULTS: Two of 53 patients, but none of 204 controls, had antibodies to NF155 (p = 0.041). The 2 patients with NF155 antibodies developed severe polyradiculoneuropathy with predominant distal weakness that was refractory to IVIg. Eight additional patients with IVIg-refractory CIDP were then identified from a national database; 2 of them with the same clinical features also had NF155 antibodies. Overall, 3 of the 4 patients with NF155 antibodies had a disabling and characteristic tremor (high amplitude, low frequency, postural, and intention). Patients' antibodies reacted with the paranodes in teased-nerve fibers and with the neuropil of rat cerebellum, brain, and brainstem. Anti-NF155 antibodies were predominantly of the IgG4 isotype in all patients. CONCLUSION:Patients with CIDP positive for IgG4 NF155 antibodies constitute a specific subgroup with a severe phenotype, poor response to IVIg, and disabling tremor. Autoantibodies against paranodal structures associate with distinct clinical features in CIDP and their identification has diagnostic, prognostic, and therapeutic implications. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that autoantibodies to NF155 identify a CIDP subtype characterized by severe neuropathy, poor response to IVIg, and disabling tremor.
Authors: Ajay Nirula; Scott M Glaser; Susan L Kalled; Frederick R Taylor; Frederick R Taylora Journal: Curr Opin Rheumatol Date: 2011-01 Impact factor: 5.006
Authors: Björn Tackenberg; Ilijas Jelcic; Anne Baerenwaldt; Wolfgang H Oertel; Norbert Sommer; Falk Nimmerjahn; Jan D Lünemann Journal: Proc Natl Acad Sci U S A Date: 2009-03-04 Impact factor: 11.205
Authors: Judy King Man Ng; Joachim Malotka; Naoto Kawakami; Tobias Derfuss; Mohsen Khademi; Tomas Olsson; Christopher Linington; Masaaki Odaka; Björn Tackenberg; Harald Prüss; Jan M Schwab; Lutz Harms; Hendrik Harms; Claudia Sommer; Matthew N Rasband; Yael Eshed-Eisenbach; Elior Peles; Reinhard Hohlfeld; Nobuhiro Yuki; Klaus Dornmair; Edgar Meinl Journal: Neurology Date: 2012-10-24 Impact factor: 9.910
Authors: Diane L Sherman; Steven Tait; Shona Melrose; Richard Johnson; Barbara Zonta; Felipe A Court; Wendy B Macklin; Stephen Meek; Andrew J H Smith; David F Cottrell; Peter J Brophy Journal: Neuron Date: 2005-12-08 Impact factor: 17.173
Authors: Emily K Mathey; Tobias Derfuss; Maria K Storch; Kieran R Williams; Kimberly Hales; David R Woolley; Abdulmonem Al-Hayani; Stephen N Davies; Matthew N Rasband; Tomas Olsson; Anja Moldenhauer; Sviataslau Velhin; Reinhard Hohlfeld; Edgar Meinl; Christopher Linington Journal: J Exp Med Date: 2007-09-10 Impact factor: 14.307
Authors: Anne Louise Oaklander; Michael Pt Lunn; Richard Ac Hughes; Ivo N van Schaik; Chris Frost; Colin H Chalk Journal: Cochrane Database Syst Rev Date: 2017-01-13